Innovative Medical Research Solutions
Advancing healthcare through cutting-edge development.
Innovative Medical Research Solutions
Advancing healthcare through cutting-edge development.
About Cytolysis Pharma
Innovative Research
At Cytolysis Pharma, we are dedicated to pioneering innovative research in the medical field. Our team focuses on developing groundbreaking therapies that aim to improve patient outcomes and advance healthcare.
PRADAB is a patented, cytolytic drug, developed for intratumoral administration, combined with aspiration of lysed tumor: a transformative therapeutic regimen for glioblastoma multiforme (GBM), the most aggressive primary brain tumor, as well as for all high-grade brain malignancies. Developed by a world-class team of neurosurgeons, clinical chemists, molecular biologists, and pharmacologists, PRADAB combines prazosin with L-2,4-diaminobutyric acid for selective tumor cells’ death by cytolysis, with neither local nor systemic side effects.